Quantcast

Latest Prostate cancer Stories

2014-05-20 08:34:45

WORCESTER, Mass. and TORONTO, May 20, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced two upcoming presentations demonstrating that certain patients with early stage breast cancer who receive AE37 may benefit in terms of reduced risk of relapse. The AE37 breast cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations will be made at the 50(th)...

2014-05-20 08:34:18

New studies highlight impact of certain conditions on prostate cancer severity, role diet may play in etiology ORLANDO, Fla., May 20, 2014 /PRNewswire-USNewswire/ -- Three new studies featuring the impact of dietary and lifestyle factors on prostate cancer will be presented during the 109(th) Annual Scientific Meeting of the American Urological Association (AUA). The research will be highlighted by study authors during a special press conference at the Orange County Convention Center...

2014-05-19 23:02:53

Transparency Market Research Report Added "Adjuvants Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012 - 2018" to its database. Browse Full Report: http://www.transparencymarketresearch.com/adjuvants-market.html. Albany, New York, USA (PRWEB) May 19, 2014 Adjuvant oncology treatment comprises of a class of cancer therapeutics which is followed after primary cancer treatment, to minimize the risk of reoccurrence of cancer. The major forms of...

2014-05-19 10:21:58

University of Cincinnati Academic Health Center About one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it. This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important. These findings are published in the May 16, 2014 edition of the journal PLOS ONE....

2014-05-18 12:20:20

ORLANDO, Fla., May 18, 2014 /PRNewswire-USNewswire/ -- With an accuracy rating of 98 percent, specially-trained dogs were able to smell volatile organic compounds (VOCs) released into urine by prostate tumors, setting the stage for a potentially new means of early prostate cancer detection, according to a new study at the 109(th) Annual Scientific Meeting of the American Urological Association (AUA). The study will be presented to the media during a special press conference on Sunday, May 18...

2014-05-18 12:20:18

Panel discusses changes in a man's sexual function after a bilateral nerve-sparing radical prostatectomy and in those with LUTS/BPH ORLANDO, Fla., May 18, 2014 /PRNewswire-USNewswire/ -- Two studies evaluating the sexual function in men with Lower Urinary Tract Symptoms (LUTS) as well as post bilateral nerve-sparing radical prostatectomy will be presented to the media at a special press conference during the 2014 Annual Scientific Meeting of the American Urological Association (AUA). Tobias...

2014-05-17 12:20:17

Panel discusses long-term effect on quality of life ORLANDO, Fla., May 17, 2014 /PRNewswire-USNewswire/ -- A series of studies evaluating the outcomes, benefits, concerns and quality of life of men undergoing active surveillance for prostate cancer will be presented to media at a special press conference during the 2014 Annual Scientific Meeting of the American Urological Association (AUA). Stacy Loeb, MD, assistant professor at New York University, New York, NY, will moderate the session,...

2014-05-16 16:24:58

Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD CITY, Calif., May 16, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that groundbreaking results from three studies of the Oncotype DX(®) prostate cancer test were published in European Urology. The peer-reviewed publication highlights studies that focus on addressing the need...

2014-05-16 12:20:36

UC Health News Just because you can’t see something doesn’t mean it’s not there. Brain tumors are an extremely serious example of this and are not only difficult to treat—both adult and pediatric patients have a five-year survival rate of only 30 percent—but also have even been difficult to image, which could provide important information for deciding next steps in the treatment process. However, Cincinnati Cancer Center research studies published in an April online issue...

2014-05-16 08:26:14

SAN DIEGO, May 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of the Decipher® Portal Professional, a mobile app designed for iPad tablets that allows registered medical practitioners to use and understand genomic information about prostate cancer and how it can impact their clinical practice. It offers physicians the opportunity to explore Decipher clinical data on interactive graphs, engage in hands-on exploration of clinical use scenarios and learn more...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.